|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for GLRX2 |
 Gene summary |
| Basic gene Info. | Gene symbol | GLRX2 |
| Gene name | glutaredoxin 2 | |
| Synonyms | CGI-133|GRX2 | |
| Cytomap | UCSC genome browser: 1q31.2 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001243399.1, NM_016066.4,NM_197962.2, | |
| Description | bA101E13.1 (GRX2 glutaredoxin (thioltransferase) 2) | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 606820 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000023572 | ||
| HPRD : 12112 | ||
| Vega : OTTHUMG00000035677 | ||
| Protein | UniProt: Q9NS18 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_GLRX2 | |
| BioGPS: 51022 | ||
| Pathway | NCI Pathway Interaction Database: GLRX2 | |
| KEGG: GLRX2 | ||
| REACTOME: GLRX2 | ||
| Pathway Commons: GLRX2 | ||
| Context | iHOP: GLRX2 | |
| ligand binding site mutation search in PubMed: GLRX2 | ||
| UCL Cancer Institute: GLRX2 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0010033 | response to organic substance | 11397793 | GO:0042542 | response to hydrogen peroxide | 11397793 |
| Top |
| Ligand binding site mutations for GLRX2 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | S76,K74 | T75K | LUAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for GLRX2 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | S76 | T75K | -1.2490011 | K74 | T75K | -1.2490011 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for GLRX2 from PDB |
| Top |
| Differential gene expression and gene-gene network for GLRX2 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for GLRX2 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for GLRX2 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved|nutraceutical | DB00143 | Glutathione | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of GLRX2 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of GLRX2 |
| Multiple alignments for Q9NS18 in multiple species |
| LBS | AA sequence | # species | Species | A134 | TFIGGATDTHR | 2 | Homo sapiens, Bos taurus | A134 | RFIGGAADTHR | 1 | Mus musculus | A134 | IFIGGAADTHR | 1 | Rattus norvegicus | C77 | FSKTSCSYCTM | 2 | Homo sapiens, Bos taurus | C77 | FSKTSCSYCSM | 1 | Mus musculus | C77 | FSKSSCSYCSM | 1 | Rattus norvegicus | G133 | GTFIGGATDTH | 2 | Homo sapiens, Bos taurus | G133 | GRFIGGAADTH | 1 | Mus musculus | G133 | GIFIGGAADTH | 1 | Rattus norvegicus | H88 | AKKIFHDMNVN | 2 | Mus musculus, Rattus norvegicus | H88 | AKKLFHDMNVN | 1 | Homo sapiens | H88 | AKNLFHDMNVN | 1 | Bos taurus | K74 | VVIFSKTSCSY | 3 | Homo sapiens, Mus musculus, Bos taurus | K74 | VVIFSKSSCSY | 1 | Rattus norvegicus | K84 | YCSMAKKIFHD | 2 | Mus musculus, Rattus norvegicus | K84 | YCTMAKKLFHD | 1 | Homo sapiens | K84 | YCTMAKNLFHD | 1 | Bos taurus | K85 | CSMAKKIFHDM | 2 | Mus musculus, Rattus norvegicus | K85 | CTMAKKLFHDM | 1 | Homo sapiens | K85 | CTMAKNLFHDM | 1 | Bos taurus | P122 | GERTVPRIFVN | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | Q109 | YGNQFQDALYK | 1 | Homo sapiens | Q109 | YGNQFQDALHK | 1 | Mus musculus | Q109 | YGSQFQEALYK | 1 | Rattus norvegicus | Q109 | YGSQFQDALHK | 1 | Bos taurus | S76 | IFSKTSCSYCT | 2 | Homo sapiens, Bos taurus | S76 | IFSKTSCSYCS | 1 | Mus musculus | S76 | IFSKSSCSYCS | 1 | Rattus norvegicus | S78 | SKTSCSYCTMA | 2 | Homo sapiens, Bos taurus | S78 | SKTSCSYCSMA | 1 | Mus musculus | S78 | SKSSCSYCSMA | 1 | Rattus norvegicus | T120 | MTGERTVPRIF | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | T135 | FIGGATDTHRL | 2 | Homo sapiens, Bos taurus | T135 | FIGGAADTHRL | 2 | Mus musculus, Rattus norvegicus | V121 | TGERTVPRIFV | 4 | Homo sapiens, Mus musculus, Rattus norvegicus, Bos taurus | Y79 | KTSCSYCTMAK | 2 | Homo sapiens, Bos taurus | Y79 | KTSCSYCSMAK | 1 | Mus musculus | Y79 | KSSCSYCSMAK | 1 | Rattus norvegicus | Y94 | DMNVNYKVVEL | 3 | Homo sapiens, Rattus norvegicus, Bos taurus | Y94 | DMNVNYKAVEL | 1 | Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |